Isofol Medical AB today announced the start of data analysis of the multi-center, global Phase III AGENT Study investigating arfolitixorin in combination with 5-FU, oxaliplatin and bevacizumab in advanced, metastatic colorectal cancer (mCRC). The kick-off of the read-out process follows discussions with the U.S. Food and Drug Administration (FDA) on the censoring rules and the number of PFS events required to start the data gathering and analysis. Isofol will determine the number of PFS events for cut-off, which will then be considered by the FDA during the NDA review.
The diligent review of options for a revised SAP led to new considerations for analyzing the data. Isofol will now submit analyses of the study based on 490 patients enrolled in the study (Japanese patients previously in addendum added to main study) and both the original and new censoring rules will be included in the New Drug Application (NDA). The integrity of the AGENT Study remains strong. Isofol is firmly focused on a comprehensive analysis and expects it will take two – four months from the start of the analysis before top-line results can be communicated.
Colorectal cancer is the third leading cause of cancer in the world and the second leading cause of cancer mortality with almost one million deaths in 2020. Recent advancements in mCRC treatment have focused on targeted therapies for select populations and still require combination with 5-FU based chemotherapy regimens for meaningful results during treatment. This means that almost all first line mCRC patients will receive a folate containing regimen as part of standard of care.
“There is a profound unmet need in metastatic colorectal cancer, yet few therapies are being studied to benefit the majority of patients vs. specific targets,” said Ulf Jungnelius, CEO of Isofol. “At Isofol, we have been singularly focused on identifying a simple and more effective modernization of the standard of care to further reduce the tumor burden and increase life span for more patients.”
For the past 40 years, 5-FU has been administered to more than 70 percent of patients with mCRC in combination with leucovorin/levoleucovorin and other cytostatics. Despite these combinations, only a limited portion of patients become eligible for surgical resection (higher in liver-limited disease), an effective way to achieve sustainable outcomes. And only 10 percent of people living with mCRC survive five years after diagnosis. Arfolitixorin is the first and only immediately active folate that bolsters 5-FU, enhancing its tumor-killing effect.